Type III interferon-induced CBFβ inhibits HBV replication by hijacking HBx

Area of Science:

• Virology
• Immunology
• Molecular Biology

Background:

• Chronic Hepatitis B virus (HBV) infection is a global health concern with limited treatment options.
• Understanding host-pathogen interactions is crucial for developing effective hepatitis B therapies.
• HBV infection is known to induce type-III interferon but not type-I or type-II interferon.

Purpose of the Study:

• To identify host factors involved in restricting HBV replication.
• To elucidate the role of type-III interferon in inducing antiviral responses against HBV.
• To investigate the molecular mechanisms underlying HBV-host interactions.

Main Methods:

• Identification of HBV restriction factors using cellular assays.
• Analysis of interferon-stimulated gene induction in response to HBV infection.
• Investigation of protein-protein interactions between viral and host factors (CBFβ, HBx, HBsAg).
• Assessment of CBFβ expression levels in HBV patients and healthy individuals.

Main Results:

• CBFβ was identified as an HBV restriction factor specifically induced by type-III interferon.
• Type-III interferon-induced IL-10 promoted CBFβ production.
• CBFβ stabilized itself through interaction with HBx but inhibited HBx-mediated HBV replication.
• CBFβ expression was reduced in HBV patients, and HBV components (HBsAg) inhibited type-III interferon-induced CBFβ expression and antiviral activity.

Conclusions:

• Type-III interferon-induced CBFβ is a key factor in inhibiting HBV replication.
• The HBx-CBFβ-HBsAg axis represents a novel molecular mechanism in HBV-host interactions.
• HBV actively suppresses antiviral responses, including type-III interferon signaling, contributing to viral persistence.